Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 33,524 |
|
|||||
| News | - | ||||||
| Day High | 7.66 | Low High |
|||||
| Day Low | 7.26 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Verastem Inc | VSTM | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.10 | 1.35% | 7.51 | 12:13:22 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 7.43 | 7.26 | 7.66 | 7.41 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 446 | 33,524 | $ 7.49 | $ 251,140 | - | 3.87 - 15.18 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 12:17:36 | 1 | $ 7.505 | USD |
Verastem Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 189.76M | 25.27M | - | 2.6M | -73.81M | -2.92 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Verastem News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VSTM Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 6.47 | 7.7899 | 6.45 | 7.17 | 85,146 | 1.04 | 16.07% |
| 1 Month | 7.00 | 7.7899 | 5.94 | 6.64 | 67,516 | 0.51 | 7.29% |
| 3 Months | 9.55 | 10.2978 | 5.94 | 7.80 | 83,450 | -2.04 | -21.36% |
| 6 Months | 11.38 | 12.00 | 5.94 | 9.00 | 164,609 | -3.87 | -34.01% |
| 1 Year | 4.62 | 15.18 | 3.87 | 9.33 | 906,846 | 2.89 | 62.55% |
| 3 Years | 26.04 | 59.22 | 3.474 | 23.71 | 1,779,524 | -18.53 | -71.16% |
| 5 Years | 55.68 | 59.22 | 3.474 | 23.79 | 2,343,409 | -48.17 | -86.51% |
Verastem Description
| Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic, and other advanced cancers. |
